NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), of the important May 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Civitas Resources, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Class Action - Shareholders of Civitas Resources may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Investors can join the prospective class action by submitting a form or contacting the law firm directly [2]. Group 2: Financial Performance and Impact - On February 24, 2025, Civitas Resources reported earnings that missed estimates by $0.16, with quarterly revenue of $1.29 billion, falling short of the consensus estimate of $1.3 billion [3]. - Following the earnings report, Civitas announced the termination of its chief operating officer and chief transformation officer, which contributed to an 18% drop in the stock price on February 25, 2025 [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized as a leader in the field [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged misleading statements regarding its Iomab-B Biologics License Application during the Class Period from October 31, 2022, to August 2, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Actinium made false statements and failed to disclose critical information about the likelihood of FDA approval for its Iomab-B BLA [5]. - Specific allegations include that data from the Sierra Trial was unlikely to meet FDA guidelines, and additional analyses provided to the FDA were also unlikely to satisfy approval requirements [5]. - As a result of these misleading statements, investors reportedly suffered damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Actinium securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atkore Inc. (NYSE: ATKR) between August 2, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Atkore common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FMC Corporation (NYSE: FMC) between November 16, 2023 and February 4, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased FMC securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Ready Capital common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Target Corporation common stock between August 26, 2022, and November 19, 2024, of the April 1, 2025, deadline to become a lead plaintiff in a class action lawsuit related to misleading statements made by Target regarding its ESG and DEI initiatives [1][4]. Group 1: Class Action Details - Investors who bought Target stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][6]. - The deadline to move the Court to serve as lead plaintiff is April 1, 2025, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Allegations Against Target - The lawsuit claims that Target misled investors with false statements about its ESG and DEI mandates, which led to customer boycotts following the 2023 LGBT-Pride Campaign [4]. - The negative impact of the Campaign resulted in a decline in Target's stock price and sales falling for the first time in six years [5]. - It is alleged that Target's CEO and Board did not disclose known risks associated with the 2023 and 2024 Campaigns, leading to investors purchasing stock at artificially inflated prices [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Class A common stock of The Trade Desk, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the specified Class Period [1][5]. Group 1: Class Action Details - The Class Period for the lawsuit is from May 9, 2024, to February 12, 2025, and the lead plaintiff deadline is April 21, 2025 [1]. - Investors who purchased Trade Desk Class A common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against The Trade Desk - The lawsuit alleges that Trade Desk made false and misleading statements regarding its business operations, particularly related to the rollout of its AI forecasting tool, Kokai [5]. - Specific claims include significant execution challenges in rolling out Kokai, delays in the rollout, and negative impacts on revenue growth due to these challenges [5]. - The lawsuit asserts that the positive statements made by the defendants about Trade Desk's business were materially false and misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., March 21, 2025. Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fee ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Intellia Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Intellia securities between July 30, 2024, and January 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Background - The lawsuit claims that during the Class Period, Intellia provided misleading information regarding its Phase 1/2 study for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-associated lung disease [5]. - Defendants allegedly failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference due to cost-effectiveness and efficiency, making NTLA-3001 an inefficient program [5].